HIE market: Take a deep breath

To be in the arena of health information exchanges (HIEs) right now is to be in a state of unrest as disruptive technologies and business models begin integrating themselves into the clinical collective consciousness. And yet, rattling the IT cages most likely settles into creature comforts once the providers become comfortable with the ephemeral nature of the state of HIEs.

Nearly 10 years ago, my father bought a new computer. This was not the first time nor would it be the last time that a new machine graced the household, but it was the first time I encountered a personal computer where the manufacturer failed to include a floppy disk drive. Surely, this was a factory error; at least that’s what I believed when I informed my father that the computer was “defective.” I had yet to become accustomed to the mystical USB drive.

Today, I could hardly do any work without the portability of a portable USB drive. What once seemed disruptive and preventive from me at the time now is commonplace. With that thought in mind, I believe that while HIE growing pains are to be expected, we can take in a large breath and understand that it won’t all be bad.

In the past month, the National eHealth Collaborative released its 2011 study on 12 sustainable HIEs, where it was found that some common successful HIE business models include participants who are paying fees to connect into their network.

There’s a lot of optimism for accountable care organizations (ACOs) from the market, as in a Health Affairs article that posits that health reform efforts will depend on creating new and better ways to organize and pay for healthcare. On the flip side, the Commonwealth Fund released a report asserting that providers do not have the current infrastructure to take on and manage risk successfully in relation to ACOs.

As far as new developments, there’s plenty of activity to chum the waters. In addition to President Obama beginning an insurance exchange roll-out, New Hampshire’s statewide health information organization went live.

If you have any questions or would like to speak with me about the HIE marketplace, please send an email to jbyers@trimedmedia.com.

Jeff Byers

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.